Click here for more information about laboratory operations and procedures
If you have additional questions regarding this test, please call: 415-353-1667
|Performed by||Medical Genomics – Molecular Diagnostics|
|In House Availability||Run 1x per week as needed, Tuesday or Thursday, day shift only|
|Method||PCR followed by reverse dot blot hybridization with allele-specific probes|
|Collection Instructions||Avoid hemolysis. Due to stability issues these samples should only be collected at UCSF Monday through noon Friday.
Do not collect sample in heparin. Keep sample refrigerated for overnight or longer storage.
For UCSF Samples (from remote sites) Click here for sample collection instructions
For NON-UCSF Samples Click here for Requisition form & Account set-up instructions. Note we only do institutional billing.
|Container type||Lavender top (EDTA)|
|Amount to Collect||3 mL blood|
|Sample type||EDTA Whole blood|
|Preferred volume||3 mL|
|Min. Volume||0.5 mL|
|UCSF Rejection Criteria||Insufficient sample received.
Samples > 5 days old when received
|Processing notes||Do not freeze blood. Refrigerate sample if storage is required.
Ship to China Basin Molecular Diagnostics
|Normal range||C/C rs12079860, T/T rs8099917|
|Synonyms||Interleukin 28B, rs12979860, rs8099917|
|Stability||Refrigerated 1 week|
|Turn around times||10-14 days|
|Additional information||An interpretation of this test by a laboratory physician will automatically be performed and billed for separately.
Patients infected with Hepatitis C are often treated with pegylated interferon/ribavirin therapy (PEG/RBV). The sustained viral response to this therapy can be predicted by genotyping of SNPs rs12979860 (C>T) and rs8099917 (T>G).
Thus, a C/C genotype at rs12979860 represents a responder allele and is associated with a 2-3 fold greater rate of SVR compared to C/T and T/T alleles.
Conversely, there is evidence that heterozygosity for the C/T genotype of rs12979860, when coupled with the T/T genotype of SNP rs8099917 (T>G), predicts a less favorable outcome than the C/C genotype alone, but a higher SVR than the T/G or G/G genotypes at rs8099917.
Thus, genotyping of both SNPs is warranted for individuals infected with Hepatitis C and contemplating PEG/RBV therapy.
This PCR based allele-specific oligonucleotide assay will genotype individuals at both rs12979860 and rs8099917 and provide favorable and less favorable SVR prediction rates based on the combined genotypes.
|LDT or Mod FDA?||Yes|
|Last Updated||8/21/2014 8:51:11 AM|